# Compound Sodium Alginate Double Action Chewable Tablet Symptomatic Relief Study

> **NCT01869491** · PHASE3 · COMPLETED · sponsor: **Reckitt Benckiser Healthcare (UK) Limited** · enrollment: 1107 (actual)

## Conditions studied

- Gastroesophageal Reflux Disease
- Dyspepsia

## Interventions

- **DRUG:** Compound Sodium Alginate Double Action Chewable Tablets
- **DRUG:** Matching placebo tablets

## Key facts

- **NCT ID:** NCT01869491
- **Lead sponsor:** Reckitt Benckiser Healthcare (UK) Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06-05
- **Primary completion:** 2014-05
- **Final completion:** 2014-05
- **Target enrollment:** 1107 (ACTUAL)
- **Last updated:** 2025-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01869491

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01869491, "Compound Sodium Alginate Double Action Chewable Tablet Symptomatic Relief Study". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01869491. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*